方法：回顾性分析我院2017-12/2018-12非缺血型CRVO合并重度阻塞性睡眠呼吸暂停低通气综合征患者66例66眼资料，其中30例患者30眼接受雷珠单抗和视网膜激光光凝联合无创正压通气(观察组)，36例36眼患者仅接受雷珠单抗和视网膜激光光凝治疗(对照组)。对比分析两组患者治疗前，治疗1、3、6mo的病变部位视网膜厚度及最佳矫正视力(BCVA)的差异。

结果：两组患者不同时间点视网膜厚度、BCVA比较均有差异(P<0.05)。治疗3、6mo，观察组患者视网膜厚度、BCVA均显著低于对照组患者(P<0.01)。对照组患者治疗3、6mo视网膜厚度的无差异(P>0.05)，其余各时间点及观察组的各时间点两两比较有差异(P<0.05)； 观察组患者治疗1、3、6mo BCVA均显著优于治疗前(P<0.05)，对照组患者治疗3、6mo BCVA均显著优于患者治疗1mo(P<0.05)，其余两两比较，差异均无统计学意义(P>0.05)。

结论：无创正压通气治疗有利于提高非缺血型CRVO合并重度阻塞性睡眠呼吸暂停低通气综合征患者的治疗效果。

METHODS: A retrospective analysis was performed on 66 patients(66 eyes)with nonischemic central retinal vein occlusion combined with severe obstructive sleep apnea hypopnea syndrome in our hospital from December 2017 to December 2018. 30 of the patients(30 eyes)received intraocular anti-vascular therapy with Lucentis and retinal laser irradiation therapy combined with noninvasive positive pressure ventilation(observation group). Totally 36 patients(36 eyes)only received intraocular anti-vascular therapy with Lucentis and retinal laser irradiation therapy(control group). The differences of the best corrected visual acuity(BCVA)and retinal thickness at lesion sites were compared and analyzed between two groups before treatment and at the 1mo, 3mo and 6mo after treatment.

RESULTS: There were statistically significant differences of both retinal thickness and BCVA between two groups at different time points(P<0.05). Both retinal thickness and BCVA of the observation group were lower than those of the control group at the 3 and 6mo after treatment(P<0.01). There was no significant difference between the retinal thickness of the 3mo after treatment and that of the 6mo after treatment in the control group(P>0.05), while there were significant differences of retinal thickness between two groups of the other time points in the control group or any two groups of the time points in the observation group(P<0.05); BCVAs of the 1, 3 and 6mo after treatment were significantly lower than that of before treatment in the observation group(P<0.05), while the BCVAs of the 3, 6mo after treatment were significantly higher than that of the 1mo after treatment in the control group(P<0.05), but no significant difference of BCVA was observed between any two group of the other time points in the observation group or control group(P>0.05).

CONCLUSION: Noninvasive positive pressure ventilation is beneficial for patients with nonischemic(RVO)combined with severe obstructive sleep apnea hypopnea syndrome to improve the therapeutic effect.